Update shared on06 Aug 2025
Fair value Decreased 28%The sharp reduction in Inspire Medical Systems’ consensus price target from $210.73 to $151.00 reflects a meaningful deterioration in both net profit margin and expected revenue growth.
What's in the News
- Company lowered full-year 2025 revenue guidance to $900–$910 million, down from prior guidance of $940–$955 million.
- Projected revenue now implies 12–13% growth over 2024's $802.8 million.
- Gross margin guidance for 2025 maintained at 84–86%.
- Diluted net income per share guidance reduced to $0.40–$0.50, compared to previous guidance of $2.20–$2.30.
Valuation Changes
Summary of Valuation Changes for Inspire Medical Systems
- The Consensus Analyst Price Target has significantly fallen from $210.73 to $151.00.
- The Net Profit Margin for Inspire Medical Systems has significantly fallen from 11.32% to 8.32%.
- The Consensus Revenue Growth forecasts for Inspire Medical Systems has significantly fallen from 16.8% per annum to 14.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.